NO20025543D0 - Profylaktisk og terapeutisk behandling av infeksjoner og andre sykdommer med mono- og disakkaridbaserte forbindelser - Google Patents

Profylaktisk og terapeutisk behandling av infeksjoner og andre sykdommer med mono- og disakkaridbaserte forbindelser

Info

Publication number
NO20025543D0
NO20025543D0 NO20025543A NO20025543A NO20025543D0 NO 20025543 D0 NO20025543 D0 NO 20025543D0 NO 20025543 A NO20025543 A NO 20025543A NO 20025543 A NO20025543 A NO 20025543A NO 20025543 D0 NO20025543 D0 NO 20025543D0
Authority
NO
Norway
Prior art keywords
infections
disaccharide
prophylactic
mono
diseases
Prior art date
Application number
NO20025543A
Other languages
English (en)
Other versions
NO20025543L (no
NO331939B1 (no
Inventor
David H Persing
Richard Thomas Crane
Gary T Elliot
J Terry Ulrich
Michael J Lacy
David A Johnson
Jory R Baldridge
Rong Wang
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO20025543D0 publication Critical patent/NO20025543D0/no
Publication of NO20025543L publication Critical patent/NO20025543L/no
Publication of NO331939B1 publication Critical patent/NO331939B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
NO20025543A 2000-05-19 2002-11-19 Anvendelse av mono- og disakkarid-baserte forbindelser for fremstilling av et farmasøytisk preparat for lindring eller forebygging av infeksiøs sykdom, autoimmun sykdom eller allergisk tilstand NO331939B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20582000P 2000-05-19 2000-05-19
US28156701P 2001-04-04 2001-04-04
PCT/US2001/016327 WO2001090129A2 (en) 2000-05-19 2001-05-18 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds

Publications (3)

Publication Number Publication Date
NO20025543D0 true NO20025543D0 (no) 2002-11-19
NO20025543L NO20025543L (no) 2003-01-08
NO331939B1 NO331939B1 (no) 2012-05-07

Family

ID=26900794

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025543A NO331939B1 (no) 2000-05-19 2002-11-19 Anvendelse av mono- og disakkarid-baserte forbindelser for fremstilling av et farmasøytisk preparat for lindring eller forebygging av infeksiøs sykdom, autoimmun sykdom eller allergisk tilstand

Country Status (21)

Country Link
US (1) US6800613B2 (no)
EP (2) EP2000144A1 (no)
JP (1) JP5004261B2 (no)
KR (1) KR100829674B1 (no)
CN (1) CN1606446A (no)
AT (1) ATE395923T1 (no)
AU (3) AU2001269695B2 (no)
BR (1) BR0110975A (no)
CA (1) CA2409221C (no)
CY (1) CY1108211T1 (no)
DE (1) DE60134134D1 (no)
DK (1) DK1284740T3 (no)
ES (1) ES2305086T3 (no)
HU (1) HU230847B1 (no)
IL (3) IL152935A0 (no)
MX (1) MXPA02011486A (no)
NO (1) NO331939B1 (no)
NZ (1) NZ522755A (no)
PL (1) PL206832B1 (no)
PT (1) PT1284740E (no)
WO (1) WO2001090129A2 (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US20030105032A1 (en) * 2000-05-19 2003-06-05 Persing David H. Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
CN1575184A (zh) * 2001-09-07 2005-02-02 波士顿大学理事会 治疗免疫复合物相关疾病的方法和组合物
EP1302206A1 (en) * 2001-10-11 2003-04-16 Universitair Medisch Centrum Utrecht Methods and means for the use of the adventitial toll-like receptor
WO2003066065A1 (en) 2002-02-04 2003-08-14 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
CA2492446A1 (en) 2002-07-08 2004-01-15 David A. Johnson Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2558012C (en) * 2004-03-05 2012-05-01 Mayo Foundation For Medical Education And Research Animals with reduced body fat and increased bone density
RU2007132123A (ru) * 2005-01-27 2009-03-10 Новартис Вэксинс Энд Диагностикс Инк. (Us) Способ определения эффективности средства, направленного против первичного муковисцидозного повреждения
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US20090136509A1 (en) * 2007-10-31 2009-05-28 Simon Blake Use of Toll-Like Receptor 4 Antagonists for the Treatment or Prevention of Osteoarthritic Conditions
WO2010141861A1 (en) 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9676819B2 (en) * 2010-09-22 2017-06-13 Innavac Pty Ltd Immunostimulatory method
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
BR112015023502A2 (pt) 2013-03-15 2017-07-18 Glaxosmithkline Biologicals Sa composição, e, métodos para intensificar uma resposta imune e melhorar ou prevenir substancialmente uma doença infecciosa, uma doença autoimune, ou uma condição alérgica em um indivíduo
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CA2942234A1 (en) 2014-03-12 2015-09-17 Glaxosmithkline Biologicals S.A. Liposomal compositions for mucosal delivery
JP2017511802A (ja) 2014-03-12 2017-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原リポソーム製剤
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2017013603A1 (en) 2015-07-21 2017-01-26 Glaxosmithkline Biologicals Sa Adjuntive immunotherapy for the prevention or treatment of infectious disease
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
BR112018002520A2 (pt) 2015-08-06 2018-09-18 Glaxosmithkline Ip Dev Ltd Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
MX363780B (es) 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
EP3440072B1 (en) 2016-04-07 2020-01-29 GlaxoSmithKline Intellectual Property Development Ltd Heterocyclic amides useful as protein modulators
US10981901B1 (en) 2016-04-07 2021-04-20 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US10604531B2 (en) 2016-05-05 2020-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
EP3487503A1 (en) 2016-07-20 2019-05-29 GlaxoSmithKline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
CN110225983A (zh) 2016-12-01 2019-09-10 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法
WO2018204302A1 (en) 2017-05-01 2018-11-08 Vanderbilt University Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
IL276608B2 (en) 2018-02-12 2024-04-01 Inimmune Corp TOLL-like receptor ligands
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN114222760A (zh) 2019-06-26 2022-03-22 葛兰素史密斯克莱知识产权发展有限公司 Il1rap结合蛋白
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CA3146900A1 (en) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
US20210069321A1 (en) 2019-09-09 2021-03-11 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
TW202128755A (zh) 2019-09-27 2021-08-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 抗原結合蛋白
CN112999233B (zh) * 2019-12-19 2023-10-20 中国医学科学院药物研究所 一类来源于赤芍的单萜苷类化合物及其制法和应用
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
JPWO2022102652A1 (no) * 2020-11-11 2022-05-19
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
CA3212345A1 (en) 2021-03-02 2022-09-09 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6764840B2 (en) * 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6368604B1 (en) * 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
DE69920915T2 (de) * 1998-07-14 2006-02-16 Wyeth Holdings Corp. Monophosphoryllipid a enthaltende adjuvans- und impfstoffzusammensetzungen
US6013640A (en) 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
WO2000026384A1 (en) * 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
EP1206190A1 (en) * 1999-08-06 2002-05-22 Corixa Corporation Vaccines for the treatment of autoimmune disease
AU1392801A (en) * 1999-11-10 2001-06-06 Smithkline Beecham Biologicals (Sa) Casb7434, an antigen over-expressed in colon cancer
US6699846B2 (en) * 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders

Also Published As

Publication number Publication date
IL186495A0 (en) 2008-01-20
CA2409221C (en) 2010-10-26
US20020077304A1 (en) 2002-06-20
CA2409221A1 (en) 2001-11-29
AU6969501A (en) 2001-12-03
HU230847B1 (en) 2018-08-28
MXPA02011486A (es) 2004-01-26
AU2007202117B2 (en) 2011-01-27
IL152935A (en) 2009-08-03
EP1284740A2 (en) 2003-02-26
IL152935A0 (en) 2003-06-24
EP1284740B1 (en) 2008-05-21
BR0110975A (pt) 2004-03-23
PL365169A1 (en) 2004-12-27
PT1284740E (pt) 2008-07-09
AU2001269695B2 (en) 2007-02-15
US6800613B2 (en) 2004-10-05
HUP0301815A2 (hu) 2003-09-29
KR20030031485A (ko) 2003-04-21
JP2004508292A (ja) 2004-03-18
PL206832B1 (pl) 2010-09-30
NO20025543L (no) 2003-01-08
WO2001090129A3 (en) 2002-06-06
IL186495A (en) 2010-12-30
KR100829674B1 (ko) 2008-05-16
NZ522755A (en) 2004-05-28
CY1108211T1 (el) 2014-02-12
EP2000144A1 (en) 2008-12-10
AU2007202117A1 (en) 2007-05-31
DK1284740T3 (da) 2008-08-04
HUP0301815A3 (en) 2009-08-28
WO2001090129A2 (en) 2001-11-29
ATE395923T1 (de) 2008-06-15
DE60134134D1 (de) 2008-07-03
CN1606446A (zh) 2005-04-13
ES2305086T3 (es) 2008-11-01
NO331939B1 (no) 2012-05-07
JP5004261B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
NO20025543L (no) Profylaktisk og terapeutisk behandling av infeksjoner og andre sykdommer med mono- og disakkaridbaserte forbindelser
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
WO2002002506A3 (en) Compounds to treat alzheimer's disease
ATE209251T1 (de) Knochen- und knorpel-bildung hervorrufende proteine
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ES2166381T3 (es) Tratamiento de enfermedades vasculares hiperproliferativas.
NO993847D0 (no) Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
NO20010593L (no) Preparat og fremgangsmÕte for behandling av Peyronies sykdom og andre subdermale plakkmanifestasjonsforstyrrelser
DE69628852D1 (de) Therapeutische medizinische kleidung für narben und entsprechendes verfahren
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
NO20015969D0 (no) Forbedret sklerittprotese for behandling av presbyopi og andre öyesykdommer
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
LV10689A (lv) Dimetilpolisiloksana pielietojums kunga un zarnu trakta slimibu arstesanai
ID27276A (id) Oksazolidinon-oksazolidinon untuk merawat infeksi-infeksi mata
GB0103174D0 (en) Novel method of treatment
BR0113646A (pt) Tratamento de distúrbios inflamatórios
PT948967E (pt) Tratamento de doencas virais em suicos
ZA971607B (en) Methods of treatment of allergic diseases
DK99993D0 (da) Treatment and prophylaxis of diseases caused by parasites or bacteria
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
UA25527A (uk) Спосіб лікуваhhя гhійhої іhфекції м'яких ткаhиh
UA25749A (uk) Спосіб хірургічhого лікуваhhя виразкової хвороби шлуhка
UA9745A (uk) Спосіб лікування алергічного риніту
ATE276760T1 (de) Verfahren zur herstellung von autovakzinen zur behandlung von chlamydiosen von säugetieren und menschen

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CORIXA CORPORATION, US

MK1K Patent expired